Contact:Earle T. Holsapple III
Location:Detroit, Michigan
Email:ETH@SciTechDevelopment.com
Tel:313.254.4755
Website:http://www.scitechdevelopment.com

Company Profile

Industry Sector: Oncology Drug Development and Delivery

Company Overview: SciTech is a biopharmaceutical company engaged in research and development of products for use in the treatment of cancer. The company was founded in 2001 as a spin off from the Karmanos Cancer Institute (KCI) and Wayne State University (WSU), both located in Detroit, Michigan, to leverage KCI’s applied research in oncology drug development and specifically to solve a biopharmaceutics problem with a well characterized and promising anticancer agent, fenretinide, under clinical study at KCI.

Target Market(s): Patients with cancer and treatment facilities worldwide.

Key Value Drivers

Technology: The Company’s core technology involves an individual and drug specific drug delivery system made by forming nanospheres composed of specific phospholipids based on the physicochemical properties of the drug, in the 1st case Fenretinide, and the structural characteristics of the phospholipids. This proprietary array forms a drug—lipid nanoparticle that can be delivered parenterally or topically thereby providing intended drug concentrations at the site of individual tumors. A GMP product has been scaled up for the IV preparation.

Competitive Advantage: Maximal drug concentration at tumor site; Minimal adverse effects by using unique, chemically defined ingredients; Better control of stability, shelf life and activity; Potential as a combination drug delivery vehicle for other water soluble drugs; Targets the pancreas, a site of major concern.

Plan & Strategy: Incubate & license or sell the individual applications; partner.

*Technology funded by the NCI and being commercialized under the NIH-CAP.

Management

Leadership:
Earle Holsapple, CEO; inventor & entrepreneur in multiple industries; CEO/COO of six profitable companies; Captain, US Marine Corps; turnaround consultant
Ralph Parchment, PhD, CSO; Pharmacologist: NCI, FDA, SAIC, Hipple, WSU; Inventor; developmental therapeutics core leader
Charles Grieshaber, PhD, Director of Drug Development; Pharmacologist: FDA NCI, WSU; extensive experience in management of preclinical drug development for government & industry; 20 INDs

Scientific Advisory Board:
Michael Burns, PhD, CEO, Repromedix, Inc.
James Eliason, PhD, Scientist, Asterand, PLC
Terry Minton, PhD, Former CEO, Aptamera, Inc.
Stephen Monk, PhD, CEO, Ash Stevens, Inc.
Louis Scarmoutzos, PhD. President, MVS Solutions, Executive Consulting; Principal Advisor, NIH-CAP

Product Pipeline

Summary of Delivery Product Pipeline

- Discovery
- Preclinical
- Filed IND
- Phase I
- Phase II
- Phase III

Short Term Exit
- Topical Delivery
- Single IV Delivery (fenretinide)

Mid Term Exit
- Combination IV Delivery (Fenretinide + Cancer Drug)

Long Term Exit
- IV Delivery of Other Insoluble Retinoids

General Delivery
- Targeted Delivery
- Combination Delivery